Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sustained annual growth of more than 3.4% in sales of prostate cancer therapies from 2005 to 2015 will be driven primarily by new entries to the market that will add to, rather than replace, existing therapies in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
PR Newswire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Health Canada Opens Consultation on ‘Pause the Clock’ Proposal
The agency would be able to pause the clock for medical device applications linked together that have different review times.
FDA Approves First Immuno-Oncology Drug for Certain Patients Previously Treated for Lung Cancer
The agency said continuing approval for Opdivo may depend on the drug showing clinical benefit in future clinical trials.
FDAnews Drug Daily Bulletin
SUSTAINED 3.4% ANNUAL SALES GROWTH IN THE PROSTATE CANCER DRUG MARKET WILL BE DRIVEN BY DEVELOPMENT OF NEW THERAPIES
June 8, 2006